Clinical Trials
1,797 trialsSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
MK-3475-06B
Merck Sharp & Dohme LLC
MK-3475-06C
Merck Sharp & Dohme LLC
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
University of Pittsburgh
Nutrition Intervention Trials in Linxian Follow-up Study
National Institutes of Health Clinical Center (CC)
RHAPSODY
Asan Medical Center
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
OHSU Knight Cancer Institute
EXCEED
Eli Lilly and Company
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
Case Comprehensive Cancer Center
Hematoporphyrin Photodynamic Therapy for Esophageal Cancer
Sun Yat-sen University
NEXUS-01
Eli Lilly and Company
Registry for Esophageal and Gastroesophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
FiREBOLT
Eli Lilly and Company
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Immunome, Inc.
TNT Esophagus
Duke University
AI-Based Risk Prediction Model for Upper Digestive Tract Cancer
National Taiwan University Hospital
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
M.D. Anderson Cancer Center
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
Tianjin Medical University Cancer Institute and Hospital
PIONEER
University of Utah
HERIZON-GEA-01
Jazz Pharmaceuticals
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
M.D. Anderson Cancer Center
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Tianjin Medical University Cancer Institute and Hospital
Exercise Training After Upper Gastrointestinal Cancer Surgery
Kansai Medical University
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
Northwestern University
The Impact of Surgical Treatment on Survival in Localized Small Cell Esophageal Cancer
Jinling Hospital, China
SUNRISE
AdventHealth Translational Research Institute
ELEVATE
University of Southampton
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
Shanghai Henlius Biotech
Predicting Disease Progression and/or Recurrence in Cancer
Massachusetts General Hospital
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Rehabilitation and Recovery for Persons With Esophageal or Gastric Cancer
Region Skane
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
FREGAT I
University Hospital, Lille
18F-FSPG PET/CT as a Non-Invasive Imaging Biomarker for Treatment Response to Chemoradiation in Esophageal Cancer
M.D. Anderson Cancer Center
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
DG-03
AstraZeneca
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
AbbVie
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
Corregene Biotechnology Co., Ltd
FREJENO
University Hospital, Bordeaux
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
MK-3475-06D
Merck Sharp & Dohme LLC
Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer
Central South University
A Single-center, Single-arm Clinical Study Evaluating the Short-term Efficacy of Inflatable Mediastinoscopic-assisted Transhiatal Laparoscopic Esophagectomy for the Radical Resection of Thoracic Esophageal Cancer
Sun Yat-sen University
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen Inc.
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Alliance for Clinical Trials in Oncology